. 2020 Oct 31;56(4):841–852. doi: 10.1038/s41409-020-01101-z

Table 1.

Patients´ characteristics and outcome (n = 180).

Sex (%)	Male/Female	109/71 (61/39)
Median age (range)	[Years]	37 (16–76)
Phenotype (%)	B-ALL Ph neg	86 (48)
	B-ALL Ph pos	50 (28)
	T-ALL	44 (24)
Remission state at allo-SCT (%)	CR1 MRD neg PCR^a/FACS^b CR1 MRD pos^a+b Primary refractory	39/30 (22/16) 33 (18) 14 (8)
Remission state at allo-SCT (%)	CR2 MRD neg PCR^a/FACS^b CR2 MRD pos^a+b Relapsed refractory	4/14 (2/8) 5 (3) 41 (23)
Donor (%)	Related HLA-identical/nonidentical Unrelated HLA-identical/nonidentical	54/5 (30/3) 86/35 (48/19)
Stem cell source (%)	PB/BM	153/27 (85/15)
TBI-based conditioning (%)	Yes/no	119/61 (66/34)
GvHD prophylaxis (%)	CyA + ATG + Alemtuzumab	178 (99) 80 (44) 47 (26)
Alive/dead (%)		63/117 (35/65)
Primary cause of death (%)	PD	62 (34)
Primary cause of death (%)	NRM	55 (31)
Death within 100 days after allo-SCT (%)		29 (16)
GvHD (%)	Acute ≤ I°/≥ II°	124/56 (69/31)
GvHD (%)	Chronic no or mild/moderate or severe	131/49 (73/27)

ALL acute lymphoblastic leukemia, Ph Philadelphia chromosome, pos positive, neg negative, allo-SCT allogeneic stem cell transplantation, CR complete remission, CR1 after first induction therapy, CR2 after salvage therapy in case of relapse, MRD minimal residual disease, HLA human leukocyte antigen, PB peripheral blood, BM bone marrow, TBI total body irradiation, GvHD graft-versus-host disease, CyA cyclosporin A, ATG Anti-thymocyte Globulin, PD progressive disease, NRM non-relapse-related mortality.

^aAnalysis of Ig-/TR-gene rearrangements via RQ-PCR in 85/180 patients = 47%.

^bAnalysis via surface marker analysis by flow cytometry in 95/180 patients = 53%.